Recently, a mouse model named YG8–800, developed by Jackson Laboratories Inc. (Farmington, CT, USA), was described by Gérard and colleagues to accurately reflect the human disease with low expression of FXN (20% compared to control), a progressive neuromuscular degeneration, and the beginning of heart hypertrophy at 26 weeks [224]. This evidence concerns the gene FXN and cardiac hypertrophy.